Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The aim of the project is to develop low molecular compounds that inhibit the TNF 1 receptor (TNFR1) by using bispecific degradation inducers (BID) technologies that will be candidates for patients with rheumatoid arthritis (RA) or non-specific bowel inflammation (NZJ), e.g. Crohn’s disease and ulcerative bowel inflammation. Diseases of the type of chronic inflammation are a challenge of modern medicine. In RA or NZJ, the pathological role of pro-inflammatory cytokines has been clinically confirmed. Market-oriented drugs against TNF inhibit both receptor-dependent signal paths (TNFR1 and TNFR2), while studies indicate that initiation of inflammation is mainly dependent on the TNFR1 receptor. As part of the project, we will focus on developing a selective compound against TNFR1, thus more effective and generating fewer side effects, using the mechanism of induction of specific protein degradation in cells discovered in recent years, which will offer numerous advantages over previously used inhibitors of the activity of selected proteins.